NYSE:XON - Intrexon Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$14.47 -0.61 (-4.05 %)
(As of 10/18/2018 04:00 PM ET)
Previous Close$15.08
Today's Range$14.28 - $15.21
52-Week Range$10.26 - $20.16
Volume983,100 shs
Average Volume1.57 million shs
Market Capitalization$2.47 billion
P/E Ratio-16.42
Dividend YieldN/A
Beta1.09
Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms. The company also provides reproductive technologies and other genetic processes to cattle breeders and producers; biological insect control solutions; technologies for non-browning apple without the use of any flavor-altering chemical or antioxidant additives; commercial aquaculture products; genetic preservation and cloning technologies; genetically engineered swine for medical and genetic research; and artwork, children's toys, and novelty goods that are derived from living organisms or enabled by synthetic biology. It serves health, food, energy, environment, and consumer markets. Intrexon Corporation has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Oragenics, Inc.; Fibrocell Science, Inc.; Genopaver, LLC; S & I Ophthalmic, LLC; OvaXon, LLC; Intrexon Energy Partners, LLC; Persea Bio, LLC; Ares Trading S.A.; Intrexon Energy Partners II, LLC; Intrexon T1D Partners, LLC; AquaBounty Technologies, Inc.; Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc. The company was formerly known as Genomatix Ltd. and changed its name to Intrexon Corporation in 2005. Intrexon Corporation was founded in 1998 and is based in Germantown, Maryland.

Receive XON News and Ratings via Email

Sign-up to receive the latest news and ratings for XON and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
SymbolNYSE:XON
CUSIPN/A
Phone301-556-9900

Debt

Debt-to-Equity Ratio0.01
Current Ratio1.78
Quick Ratio1.53

Price-To-Earnings

Trailing P/E Ratio-16.42
Forward P/E Ratio-18.32
P/E GrowthN/A

Sales & Book Value

Annual Sales$230.98 million
Price / Sales8.10
Cash FlowN/A
Price / CashN/A
Book Value$4.29 per share
Price / Book3.37

Profitability

EPS (Most Recent Fiscal Year)($0.92)
Net Income$-117,010,000.00
Net Margins-82.17%
Return on Equity-16.67%
Return on Assets-11.07%

Miscellaneous

Employees1,006
Outstanding Shares129,290,000
Market Cap$2.47 billion

Intrexon (NYSE:XON) Frequently Asked Questions

What is Intrexon's stock symbol?

Intrexon trades on the New York Stock Exchange (NYSE) under the ticker symbol "XON."

How were Intrexon's earnings last quarter?

Intrexon Corp (NYSE:XON) announced its quarterly earnings results on Thursday, August, 9th. The biotechnology company reported ($0.51) earnings per share for the quarter, missing analysts' consensus estimates of ($0.23) by $0.28. The biotechnology company had revenue of $45.30 million for the quarter, compared to analyst estimates of $51.70 million. Intrexon had a negative return on equity of 16.67% and a negative net margin of 82.17%. During the same period last year, the firm earned ($0.16) EPS. View Intrexon's Earnings History.

When is Intrexon's next earnings date?

Intrexon is scheduled to release their next quarterly earnings announcement on Thursday, November 8th 2018. View Earnings Estimates for Intrexon.

What price target have analysts set for XON?

5 analysts have issued twelve-month target prices for Intrexon's shares. Their forecasts range from $12.00 to $72.00. On average, they expect Intrexon's stock price to reach $32.40 in the next year. This suggests a possible upside of 123.9% from the stock's current price. View Analyst Price Targets for Intrexon.

What is the consensus analysts' recommendation for Intrexon?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intrexon in the last year. There are currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Intrexon.

Are investors shorting Intrexon?

Intrexon saw a increase in short interest in September. As of September 28th, there was short interest totalling 32,916,752 shares, an increase of ∞ from the September 14th total of 0 shares. Based on an average daily trading volume, of 3,701,811 shares, the short-interest ratio is presently 8.9 days. Currently, 48.2% of the shares of the stock are short sold. View Intrexon's Current Options Chain.

Who are some of Intrexon's key competitors?

Who are Intrexon's key executives?

Intrexon's management team includes the folowing people:
  • Mr. Randal J. Kirk, Chairman & CEO (Age 65)
  • Mr. Rick L. Sterling, Chief Financial Officer (Age 54)
  • Mr. Donald P. Lehr, Chief Legal Officer & Corp. Sec. (Age 43)
  • Mr. Robert F. Walsh III, Sr. VP of Energy & Fine Chemicals Platforms (Age 60)
  • Mr. Jeffrey Thomas Perez, Sr. VP of Intellectual Property Affairs (Age 46)

Who are Intrexon's major shareholders?

Intrexon's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Peregrine Capital Management LLC (0.50%), Sanders Morris Harris LLC (0.08%) and Sanders Morris Harris LLC (0.00%). Company insiders that own Intrexon stock include Andrew J Last, Dean J Mitchell, Donald P Lehr, Fred Hassan, Helen Sabzevari, Jeffrey Thomas Perez, Joel D Liffman, Randal J Kirk and Robert B Shapiro. View Institutional Ownership Trends for Intrexon.

Which institutional investors are selling Intrexon stock?

XON stock was sold by a variety of institutional investors in the last quarter, including Sanders Morris Harris LLC, Peregrine Capital Management LLC and Sanders Morris Harris LLC. Company insiders that have sold Intrexon company stock in the last year include Helen Sabzevari and Joel D Liffman. View Insider Buying and Selling for Intrexon.

How do I buy shares of Intrexon?

Shares of XON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Intrexon's stock price today?

One share of XON stock can currently be purchased for approximately $14.47.

How big of a company is Intrexon?

Intrexon has a market capitalization of $2.47 billion and generates $230.98 million in revenue each year. The biotechnology company earns $-117,010,000.00 in net income (profit) each year or ($0.92) on an earnings per share basis. Intrexon employs 1,006 workers across the globe.

What is Intrexon's official website?

The official website for Intrexon is http://www.dna.com.

How can I contact Intrexon?

Intrexon's mailing address is 20374 Seneca Meadows Parkway, Germantown MD, 20876. The biotechnology company can be reached via phone at 301-556-9900 or via email at [email protected]


MarketBeat Community Rating for Intrexon (NYSE XON)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  309 (Vote Outperform)
Underperform Votes:  286 (Vote Underperform)
Total Votes:  595
MarketBeat's community ratings are surveys of what our community members think about Intrexon and other stocks. Vote "Outperform" if you believe XON will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XON will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/18/2018 by MarketBeat.com Staff

Featured Article: Discount Rate

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel